Mackenzie Financial Corp boosted its position in shares of Illumina, Inc. (NASDAQ:ILMN – Get Rating) by 4.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,398 shares of the life sciences company’s stock after acquiring an additional 628 shares during the period. Mackenzie Financial Corp’s holdings in Illumina were worth $2,654,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently bought and sold shares of ILMN. Glassman Wealth Services lifted its position in Illumina by 72.9% during the 2nd quarter. Glassman Wealth Services now owns 147 shares of the life sciences company’s stock worth $27,000 after acquiring an additional 62 shares during the last quarter. Tcwp LLC acquired a new position in shares of Illumina during the first quarter valued at about $31,000. WASHINGTON TRUST Co acquired a new position in shares of Illumina during the first quarter valued at about $35,000. WFA of San Diego LLC acquired a new position in shares of Illumina during the second quarter valued at about $37,000. Finally, Corsicana & Co. acquired a new position in shares of Illumina during the second quarter valued at about $39,000. Institutional investors and hedge funds own 86.12% of the company’s stock.
Insiders Place Their Bets
In other Illumina news, SVP Susan H. Tousi sold 500 shares of the company’s stock in a transaction dated Monday, November 7th. The shares were sold at an average price of $223.65, for a total transaction of $111,825.00. Following the sale, the senior vice president now directly owns 40,112 shares of the company’s stock, valued at $8,971,048.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.13% of the company’s stock.
Illumina Price Performance
Wall Street Analyst Weigh In
A number of research analysts have recently commented on the stock. Bank of America cut their price objective on shares of Illumina from $220.00 to $200.00 in a research report on Friday, August 12th. OTR Global lowered shares of Illumina to a “positive” rating in a research report on Wednesday, September 28th. Cowen upped their price objective on shares of Illumina from $327.00 to $350.00 in a research report on Friday, November 4th. StockNews.com started coverage on shares of Illumina in a research report on Wednesday, October 12th. They set a “hold” rating for the company. Finally, Cowen increased their price target on shares of Illumina from $327.00 to $350.00 in a research report on Friday, November 4th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, Illumina presently has an average rating of “Hold” and a consensus target price of $254.38.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.
- Get a free copy of the StockNews.com research report on Illumina (ILMN)
- Three Ways To Win The Online Gambling Industry
- Santa Claus Rally? Here’s What Needs to Happen
- Will the Return of Bob Iger Return the Magic to Disney Stock?
- Is Ardelyx is A Buy After Slip in Early 2022
- Is Tesla A Bargain Now As It Trades At Two-Year Lows?
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.